ExoLab Italy, a L’Aquila, Italy-based biotech startup specializing in the creation of products and applications based on exosomes, raised €5M in Series A funding.
Backers included dsm-firmenich Ventures, CDP Venture Capital, Linfa Fund (managed by Riello Investimenti Sgr), and Maia Ventures.
The company intends to use the funds to increase production capacity and offer new opportunities for advanced research projects.
Founded by Mariantonia Logozzi and Stefano Fais, along with Lorenzo Cilli and Valerio Carconi, and led by CEO Gabriele Campi, ExoLab Italia is a biotech startup specializing in the creation of products and applications based on plant-derived exosomes, extracted from organic Italian fruits and vegetables. Exosomes are vesicles capable of carrying antioxidants, vitamins, proteins, and lipids specific to the plant, as well as its nucleic acids. They are applied in functional actives markets, particularly in the cosmetics and dietary supplements industries, as well as in the research and development of drug delivery systems, due to their ability to be loaded with exogenous molecules and achieve unparalleled delivery efficiency.
FinSMEs
18/02/2025